[go: up one dir, main page]

NO20030304D0 - New combination of serotonin agonist (5HT2) and antagonist (5HT6) as a pharmaceutical formulation - Google Patents

New combination of serotonin agonist (5HT2) and antagonist (5HT6) as a pharmaceutical formulation

Info

Publication number
NO20030304D0
NO20030304D0 NO20030304A NO20030304A NO20030304D0 NO 20030304 D0 NO20030304 D0 NO 20030304D0 NO 20030304 A NO20030304 A NO 20030304A NO 20030304 A NO20030304 A NO 20030304A NO 20030304 D0 NO20030304 D0 NO 20030304D0
Authority
NO
Norway
Prior art keywords
antagonist
pharmaceutical formulation
new combination
serotonin agonist
serotonin
Prior art date
Application number
NO20030304A
Other languages
Norwegian (no)
Other versions
NO20030304L (en
Inventor
Sukhwinder Jossan
Bjoern M Nilsson
Kjell S Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20030304D0 publication Critical patent/NO20030304D0/en
Publication of NO20030304L publication Critical patent/NO20030304L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20030304A 2000-07-21 2003-01-20 New combination of serotonin agonist (5HT2) and antagonist (5HT6) as a pharmaceutical formulation NO20030304L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (en) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
NO20030304D0 true NO20030304D0 (en) 2003-01-20
NO20030304L NO20030304L (en) 2003-03-12

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030304A NO20030304L (en) 2000-07-21 2003-01-20 New combination of serotonin agonist (5HT2) and antagonist (5HT6) as a pharmaceutical formulation

Country Status (19)

Country Link
EP (1) EP1301476A1 (en)
JP (1) JP2004504376A (en)
KR (1) KR100845450B1 (en)
CN (1) CN1221254C (en)
AU (2) AU2001282734B2 (en)
BR (1) BR0112661A (en)
CA (1) CA2411192A1 (en)
EA (1) EA006604B1 (en)
HK (1) HK1057536A1 (en)
HU (1) HUP0301346A3 (en)
IL (1) IL154057A0 (en)
MX (1) MXPA03000548A (en)
NO (1) NO20030304L (en)
NZ (1) NZ523216A (en)
PL (1) PL360309A1 (en)
SE (1) SE0002754D0 (en)
WO (1) WO2002008178A1 (en)
YU (1) YU2603A (en)
ZA (1) ZA200210234B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525592A (en) * 2000-11-02 2004-07-30 Wyeth Corp 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (en) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 4-piperazinylindole derivatives with 5-HT6 receptor affinity
CA2450245A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
KR101020399B1 (en) * 2002-03-27 2011-03-08 글락소 그룹 리미티드 Quinoline Derivatives and Uses thereof as 5-HT6 Ligands
CL2004000826A1 (en) * 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
CN101871931A (en) 2003-07-22 2010-10-27 艾尼纳制药公司 Be used to prevent and treat associated conditions and as the diaryl and the aryl heteroaryl urea derivatives of 5-HT2A serotonin receptor modulator
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ES2358288T3 (en) * 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. COMBINATION OF AT LEAST TWO LEAGUES OF 5HT6.
JP5520051B2 (en) 2007-11-15 2014-06-11 武田薬品工業株式会社 Condensed pyridine derivatives and uses thereof
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
TW201529584A (en) 2009-06-15 2015-08-01 Takeda Pharmaceutical Pyrazinooxazepine derivatives
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
MX388281B (en) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
TW201720439A (en) 2015-07-15 2017-06-16 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as 5-HT2A serotonin receptors for the prevention and treatment of hallucinations associated with neurodegenerative diseases
CN107628981B (en) * 2017-10-31 2019-07-30 威海市妇女儿童医院 A kind of cinnamoyl sulfonylindoline compounds and its application for preparing glaucoma medicine
JPWO2019131902A1 (en) 2017-12-27 2020-12-10 武田薬品工業株式会社 Remedies for stress urinary incontinence and fecal incontinence
CN111269165A (en) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 Synthetic method of 3-arylsulfonyl indole derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
EP1301476A1 (en) 2003-04-16
JP2004504376A (en) 2004-02-12
WO2002008178A1 (en) 2002-01-31
AU8273401A (en) 2002-02-05
KR20030036599A (en) 2003-05-09
CN1221254C (en) 2005-10-05
PL360309A1 (en) 2004-09-06
BR0112661A (en) 2003-06-24
YU2603A (en) 2006-05-25
IL154057A0 (en) 2003-07-31
HK1057536A1 (en) 2004-04-08
KR100845450B1 (en) 2008-07-10
HUP0301346A3 (en) 2005-05-30
CN1443162A (en) 2003-09-17
EA006604B1 (en) 2006-02-24
AU2001282734B2 (en) 2006-10-12
EA200300183A1 (en) 2003-08-28
HUP0301346A2 (en) 2003-08-28
NO20030304L (en) 2003-03-12
SE0002754D0 (en) 2000-07-21
MXPA03000548A (en) 2004-04-05
CA2411192A1 (en) 2002-01-31
ZA200210234B (en) 2004-03-18
NZ523216A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
NO20030304D0 (en) New combination of serotonin agonist (5HT2) and antagonist (5HT6) as a pharmaceutical formulation
NO20032797D0 (en) Substituted pyridoindoles such as serotonin agonists and antagonists
DK1454901T3 (en) Pharmaceutical compositions comprising tachykinin antagonists and a serotonin reuptake inhibitor
NO20031744D0 (en) New non-imadazole compounds and pharmaceutical compositions comprising such
NO20025450L (en) New pharmaceutical composition
PT1572707E (en) NEW AROMATIC FLUOROGLICOSIDEOS DERIVATIVES, PHARMACOS CONTAINING THESE COMPOUNDS AND THEIR USE
CY2007013I1 (en) NEW PRESCRIPTIONS OF XENTIN AGONIST AND METHODS OF THEIR ADMINISTRATION
NO20003196L (en) Immediately dissolving dosage formulation
NO20030471D0 (en) Carboxamide compounds and their use as antagonists for an 11CBY receptor
DE60212044D1 (en) Test of buccal dissolution of pharmaceutically active substances
HK1042891B (en) Benzene derivatives, preparation methods thereof, and pharmaceutical compositions containing them
DK1263721T3 (en) Pharmaceutical compositions containing 3-aminoacetidine derivatives, novel derivatives and preparation thereof
NO20033143D0 (en) Pharmaceutical preparation
IS6811A (en) Pharmaceutical compositions of NMDA receptor agonists
NO20032517D0 (en) Pharmaceutical preparation containing amlodipine maleate
NO20011503D0 (en) Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, their preparation and use as anorectic drugs
NO20041008L (en) Carbazole derivatives and their use as NPY5 receptor antagonists
NO20041607L (en) Dosage regimen and pharmaceutical preparation for node prevention
NO20032142L (en) Substituted 2-phenylaminoimidazoline-phenylketone derivatives as IP antagonists
NO20040254L (en) Pharmaceutical compositions containing terbinafine and its use
DK1230230T3 (en) Derivatives of indeno-dihydrothiazole, its preparation and use as anorectic drugs
NO20015149L (en) New pharmaceutical preparation
DK1322158T3 (en) Long-release pharmaceutical compositions containing metformin and methods for their preparation
NO20043124L (en) Aminoindane derivatives such as serotonin and norepinephrine uptake inhibitors
NO20035328D0 (en) New compounds and preparations as catheps inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application